A Study of Mirikizumab (LY3074828) in Participants With Moderate to Severe Ulcerative Colitis
The main purpose of this study is to test the hypothesis that treatment with LY3074828 is superior to placebo in providing clinical benefit to participants with moderate to severe ulcerative colitis (UC). This study will also investigate how the body processes the drug.
The results of this study are not yet available.
Your participation could last up to 1 year and include 32 visits to the study center.
Here you can find out a bit more about the requirements for volunteers who took part in this study
Participant must have moderate to severe active ulcerative colitis (UC)
Participant must have evidence of ulcerative colitis extending near the rectum
Participant must not have been diagnosed with Crohn's Disease, indeterminate colitis or proctitis
Participant must not have had surgery for the treatment of ulcerative colitis or be likely to require surgery for ulcerative colitis during the study
Participant must not have received any of the following for treatment of ulcerative colitis: cyclosporine or thalidomide, corticosteroid enemas, corticosteroid suppositories, or topical treatment with 5-aminosalicyclic acid within 30 days of screening